Skip to main content
padlock icon - secure page this page is secure

A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia‐chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria

Buy Article:

$52.00 + tax (Refund Policy)

We conducted a phase II study to evaluate the efficacy and safety of dasatinib in Japanese patients with imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia (CML).
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: European LeukemiaNet 2013 recommendations; chronic myeloid leukemia; dasatinib; major molecular response; molecular response ≧4.5 log reduction

Document Type: Research Article

Publication date: December 1, 2015

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more